You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Litigation Details for Onyx Therapeutics, Inc. v. CIPLA Limited (D. Del. 2016)

✉ Email this page to a colleague

« Back to Dashboard

Onyx Therapeutics, Inc. v. CIPLA Limited (D. Del. 2016)

Docket	⤷ Sign Up	Date Filed	2016-10-24
Court	District Court, D. Delaware	Date Terminated	2023-02-21
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Parties	AUROBINDO PHARMA USA INC.
Patents	7,232,818; 7,417,042; 7,491,704; 7,737,112; 8,129,346; 8,207,125; 8,207,126; 8,207,127; 8,207,297
Attorneys	Chiemi D. Suzuki
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Small Molecule Drugs cited in Onyx Therapeutics, Inc. v. CIPLA Limited

The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .

Biologic Drugs cited in Onyx Therapeutics, Inc. v. CIPLA Limited

The biologic drugs covered by the patents cited in this case are ⤷ Sign Up and ⤷ Sign Up .

Details for Onyx Therapeutics, Inc. v. CIPLA Limited (D. Del. 2016)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2016-10-24	1	Complaint	16. United States Patent No. 7,232,818 (the “’818 Patent”), entitled “Compounds For Enzyme Inhibition…Product prior to the expiration of U.S. Patent Nos. 7,417,042; 7,232,818; 7,491,704; 7,737,112; 8,129,346;… COUNT II: INFRINGEMENT OF U.S. PATENT NO. 7,232,818 53. Plaintiff hereby realleges… THE PATENTS-IN-SUIT 15. United States Patent No. 7,417,042 (the “’042 Patent”), entitled… This is a civil action for patent infringement under the patent laws of the United States, Title	External link to document
2018-04-17	203	Redacted Document	Relevant Onyx’s U.S. Patent No. 7,737,112 (“Onyx’s formulation patent”) contains claims directed…by claims of the Patents-in-Suit. In this litigation, Onyx is asserting five patents, which are directed…alternative formulations to the patented formulations or to “design around” the Patents-in-Suit (Topics 3-5 of …own patents on formulations of carfilzomib. These defendants are effectively arguing to the Patent Office…. (“Onyx”) in the above-referenced matter. This patent infringement action, arising under the Hatch-Waxman	External link to document
2018-06-26	240	Notice of Service	Opening Expert Report on Invalidity of U.S. Patent Nos. 7,417,042; 7,737,112; 8,207,125; 8,207,126 and 8,207,127… 2016 15 May 2020 1:16-cv-00988 830 Patent None District Court, D. Delaware	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.